Roche announced the launch of its cobas Zika test for screening blood donations in markets that accept the CE Mark.
The test screens for the Zika virus in human plasma and is designed for use with the company's cobas 6800/8800 systems. Roche noted that it has been marketing the Zika test for screening blood donations in the U.S. and U.S. territories since 2017, in consultation with the Food and Drug Administration.
"Since then, the cobas Zika test has been used to screen millions of blood donations from the U.S. and Puerto Rico, helping to identify and remove more than 350 potentially infectious donations from the blood supply," Roche said in a statement.
Roche's portfolio of tests for screening blood donations also includes assays for detecting chikungunya and dengue viruses.